Cardiology · AntiarrhythmicRegulatory Approvalcommercialnear-term

FDA Grants Approval for Dofetilide ANDA212496 by Innogenix Inc.

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/5/2026, 6:02:19 AM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Innogenix Inc.'s generic Dofetilide marks a significant shift in the antiarrhythmic drug market, increasing competition and potentially impacting pricing strategies. Existing competitors must adapt to maintain their market share in light of this new entrant. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 4 ranked evidence items (2 high-relevance).

Strategic Assessment

Strategic implications include the need for existing competitors to reassess pricing and market strategies in response to the new generic entrant. The strongest clinical anchor is Hydrus® Microstent New Enrollment Post-Approval Study (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In cardiology, 4 regulatory and 0 competitive items passed relevance filtering for Dofetilide.

Competitive Pressure

The most relevant competitive pressure comes from This approval allows Innogenix Inc. to enter the market with a generic version of Dofetilide, potentially increasing competition in the antiarrhythmic drug market..

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). Relevant agencies in corpus: FDA, MHRA. The approval signifies compliance with FDA standards but does not indicate broader regulatory challenges for the industry.

Key Risks

Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Dofetilide through agency review timelines and labeling constraints if follow-through weakens.
Regulatory risk from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) could weigh on Dofetilide through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

The introduction of a generic version of Dofetilide could lead to price reductions and increased competition, affecting revenue for current market players.
Upside for Dofetilide may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Strategic implications include the need for existing competitors to reassess pricing and market strategies in response to the new generic entrant.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from Innogenix Inc. and competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
MHRAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DOFETILIDE (ORIG)
FDAmedium relevance
Entity match (dofetilide); Regulatory pathway relevance (nda)
FDA document
View source

Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Approval for Vasopressin Application ANDA212068 by Sandoz
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Grants Priority Review for NUPLAZID Supplement NDA210793
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Acute kidney injury after cytoreductive surgery and HIPEC: incidence and timing in a 10-year single-center cohort.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Dofetilide

Commercial impact

medium

The introduction of a generic version of Dofetilide could lead to price reductions and increased competition, affecting revenue for current market players.

Regulatory impact

low

The approval signifies compliance with FDA standards but does not indicate broader regulatory challenges for the industry.

What to watch

Monitor market entry timelines and pricing strategies from Innogenix Inc. and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.